Evommune (NYSE:EVMN) Director Arthur Kirsch Acquires 10,000 Shares

Evommune, Inc. (NYSE:EVMN) Director Arthur Kirsch acquired 10,000 shares of Evommune stock in a transaction dated Tuesday, July 7th. The stock was purchased at an average price of $13.30 per share, for a total transaction of $133,000.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $133,000. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Evommune Stock Performance

NYSE:EVMN opened at $13.25 on Thursday. The stock has a 50-day simple moving average of $20.83 and a 200-day simple moving average of $22.10. The stock has a market cap of $477.34 million and a P/E ratio of -1.39. Evommune, Inc. has a 1 year low of $12.07 and a 1 year high of $33.20.

Evommune (NYSE:EVMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. On average, equities research analysts predict that Evommune, Inc. will post -2.83 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EVMN. China Universal Asset Management Co. Ltd. purchased a new stake in Evommune in the fourth quarter valued at approximately $34,000. Strs Ohio purchased a new position in shares of Evommune during the first quarter worth approximately $41,000. The Manufacturers Life Insurance Company purchased a new position in shares of Evommune during the fourth quarter worth approximately $179,000. XTX Topco Ltd acquired a new position in shares of Evommune in the 4th quarter valued at $321,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Evommune in the 4th quarter valued at $335,000.

Analysts Set New Price Targets

A number of analysts have weighed in on EVMN shares. Weiss Ratings cut shares of Evommune from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Stifel Nicolaus started coverage on shares of Evommune in a report on Friday, May 1st. They issued a “buy” rating and a $54.00 target price for the company. HC Wainwright downgraded shares of Evommune from a “buy” rating to a “neutral” rating in a research report on Tuesday, June 30th. Oppenheimer started coverage on shares of Evommune in a research note on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Clear Str raised shares of Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.62.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.